Back to discover

Protein / target

Tyrosine-protein kinase JAK2

Encoded byJAK2O60674Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
18
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Non-membrane spanning protein tyrosine kinase

Strongest disease association

Colitis, Ulcerative

Via encoding gene JAK2 · Genetic evidence · score 0.82

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

3 papers · latest 2021

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Non-membrane spanning protein tyrosine kinase that phosphorylates type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins.

View complete UniProt function annotation

Non-membrane spanning protein tyrosine kinase that phosphorylates type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:15690087, PubMed:15899890, PubMed:7615558, PubMed:9188471, PubMed:9657743). Functionnally, plays a pivotal role in signal transduction and is involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. Mechanistically, following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:15690087, PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain (PubMed:9657743). Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). Up-regulates the potassium voltage-gated channel activity of KCNA3 (PubMed:25644777). Binding of CNTF or the CLCF1/CLF heterodimer to CNTFR leads to IL6ST/gp130-LIFR dimerization followed by activation of JAK1 and JAK2 which in turns phosphorylate IL6ST/gp130 and LIFR (PubMed:11294841). The tyrosine phosphorylated signaling receptors serve in turn as docking proteins for STAT3 (PubMed:11294841). Involved in the oncostatin-M-mediated signaling pathway through both type I OSM receptor complex (heterodimers composed of LIFR and IL6ST) and type II OSM receptor complex (heterodimers composed of OSMR and IL6ST) (PubMed:9188471)

Subcellular location

Endomembrane systemCytoplasmNucleus
Domains and Gene Ontology detail (118)

Domains & features

FERMSH2; atypicalProtein kinase 1Protein kinase 2

Gene Ontology

  • Ccaveola
  • Cchromatin
  • Ccytoplasm
  • Ccytoplasmic side of plasma membrane
  • Ccytosol
  • Cendosome lumen
  • Ceuchromatin
  • Cextrinsic component of cytoplasmic side of plasma membrane
  • Cextrinsic component of plasma membrane
  • Cglutamatergic synapse
  • Cmembrane raft
  • Cnucleoplasm

1132 aa · 131 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingGOIon channel gatingUniProtGrowth-factor signallingGOCell proliferation & survivalGOCell migrationGONuclear receptor signallingGO
View supporting evidence

Synaptic signalling

  • ·glutamatergic synapse
  • ·postsynapse
  • ·modulation of chemical synaptic transmission
  • ·regulation of postsynapse to nucleus signaling pathway

Ion channel gating

  • ·Non-membrane spanning protein tyrosine kinase that phosphorylates type I receptors such…

Growth-factor signalling

  • ·platelet-derived growth factor receptor signaling pathway

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

Cell migration

  • ·positive regulation of cell migration

Nuclear receptor signalling

  • ·nuclear receptor-mediated mineralocorticoid signaling pathway
View underlying pathways (25)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

STAT1LEPRSTAT5ASOCS3EPORIFNGR2STAT3IFNGR1STAT5BGHRJAK2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Arthritis, Rheumatoid1 medicine

18 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

2

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

baricitinib
Narrow target profileApprovedInhibitor

Tyrosine-protein kinase JAK2 inhibitor

Indicated for Arthritis, Rheumatoid

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

delgocitinib
ApprovedInhibitor

Janus Kinase (JAK) inhibitor

Acts on a complex — shared with JAK3, JAK1, TYK2 · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene JAK2

Gene-level evidence surfaced through the gene JAK2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Acquired polycythemia vera
0.97Well supported

Genetic evidence dominant · Open Targets 0.80

Colitis, Ulcerative
0.96Well supported

Genetic evidence dominant · Open Targets 0.72

Neoplasms
0.95Well supported

Genetic evidence dominant · Open Targets 0.69

Myelofibrosis
0.95Well supported

Clinical evidence dominant · Open Targets 0.74

Primary myelofibrosis
0.95Well supported

Clinical evidence dominant · Open Targets 0.75

View evidence synthesis (5)
Acquired polycythemia veraWell supported
0.97
agreement 0.881.00
Genetic36%Clinical32%Somatic mutation18%Animal model8%Literature7%Genetic literaturedup

Open Targets aggregate 0.80 · 5 independent evidence families · 1 not counted as duplicate

Colitis, UlcerativeWell supported
0.96
agreement 0.871.00
Genetic46%Clinical40%Somatic mutation11%Literature2%RNA expression1%

Open Targets aggregate 0.72 · 5 independent evidence families

NeoplasmsWell supported
0.95
agreement 0.861.00
Genetic31%Clinical31%Pathway17%Somatic mutation14%Literature6%

Open Targets aggregate 0.69 · 5 independent evidence families

MyelofibrosisWell supported
0.95
agreement 0.871.00
Clinical35%Genetic literature23%Somatic mutation19%Pathway12%Animal model7%Literature4%

Open Targets aggregate 0.74 · 6 independent evidence families

Primary myelofibrosisWell supported
0.95
agreement 0.861.00
Clinical36%Genetic33%Somatic mutation19%Animal model8%Literature4%

Open Targets aggregate 0.75 · 5 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Acquired polycythemia vera0.80
Primary myelofibrosis0.75
Myelofibrosis0.74
Colitis, Ulcerative0.72
Myeloproliferative disorder0.70
Crohn's Disease0.69
Neoplasms0.69
Leukemia, Myeloid, Acute0.67

Drug development

31 compounds recorded · 18 approved · 13 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 2 drugs that target this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
FEDRATINIB HYDROCHLORIDEApproval
GANDOTINIBPhase 2
XL-019Phase 3
AT-9283Phase 3
BMS-911543Phase 2
UPADACITINIB HEMIHYDRATEApproval
ZOTIRACICLIBPhase 1 2
NS-018Phase 2
TOFACITINIB CITRATEApproval
LESTAURTINIBApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (12)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

heart diseaseForce et al. (2011)regulation of catalytic activityToxCast

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via baricitinib · NCT04381936

NOT_YET_RECRUITING · via baricitinib · NCT07209267

NOT_YET_RECRUITING · via baricitinib · NCT07608796

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-06-30

    Label change: BARICITINIB (NDA207924)

    fda · regulatory · fda · via baricitinib

  2. Label change2026-06-30

    Label change: DELGOCITINIB (NDA219155)

    fda · regulatory · fda · via delgocitinib

  3. Regulatory approval2025-07-23

    Approval: DELGOCITINIB (NDA219155)

    fda · regulatory · fda · via delgocitinib

  4. New publication2025-04-16
    Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.

    Lancet (London, England) · 2025 · 12 citations · Europe PMC · via delgocitinib

  5. Regulatory approval2024-09-19

    Approval: Anzupgo (EMA)

    ema · regulatory · ema · via delgocitinib

  6. Indication expanded2022-06-13

    Indication expansion: BARICITINIB (NDA207924)

    fda · regulatory · fda · via baricitinib

  7. Indication expanded2022-05-10

    Indication expansion: BARICITINIB (NDA207924)

    fda · regulatory · fda · via baricitinib

  8. Label change2021-12-02

    Label change: BARICITINIB (NDA207924)

    fda · regulatory · fda · via baricitinib

  9. New publication2021-01-01
    Immunopathogenesis and treatment of cytokine storm in COVID-19.

    Theranostics · 2021 · 308 citations · Europe PMC · via baricitinib

  10. Safety communication2020-08-26

    Drug Safety Update: Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors

    mhra · safety · mhra · via baricitinib

  11. Safety communication2020-03-18

    Drug Safety Update: Baricitinib (Olumiant▼): risk of venous thromboembolism

    mhra · safety · mhra · via baricitinib

  12. Regulatory approval2018-05-31

    Approval: BARICITINIB (NDA207924)

    fda · regulatory · fda · via baricitinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

3 papers · to 2021

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.